跨研究实践的试验信息性:映射练习的初步发现
该研究通过快速综述、内容分析和定性访谈三种方法,比较了试验信息性的相关因素,识别出涵盖试验设计、实施和知识动员的12项良好实践行动。这些行动反映了证据、指南和利益相关者视角的一致优先事项,涉及多个参与方,适用于资助方、申办方和试验研究者。未来需应用、评估和优化这些行动。
要点
- 识别出12项覆盖试验设计、实施和知识动员的良好实践行动。
- 这些行动适用于资助方、申办方和试验研究者等多个利益相关方。
- 未来需应用、评估和优化这些行动以确保其广泛适用性。
核心结论
- 识别出的12项良好实践行动应在更广泛的映射练习中单独考虑,因其解决试验质量的广泛驱动因素并支持研究改进。
研究设计与样本
- 比较了快速综述、国际临床试验指南文件的内容分析和试验利益相关者定性访谈三种研究的结果。
主要发现
- 比较三种研究识别出12项涵盖试验设计、实施和知识动员的良好实践行动。
- 这些行动反映了证据、指南和利益相关者视角的一致优先事项。
- 所有良好实践行动均可适用于资助方和/或申办方以及试验研究者。
- 其他利益相关者包括监管机构、患者或社区代表、伦理机构、政策制定者等。
临床怎么用
- 资助方、申办方和试验研究者可应用这些良好实践行动来提升试验信息性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trial informativeness is influenced by multiple interacting factors across trial design, conduct, and knowledge mobilization, yet how these elements align across current research practices remains unclear. This short communication presents the initial results of a mapping exercise aimed at identifying areas of convergence across three related research strands with the goal of clarifying shared processes and actions that underpin informative trials and the broader research systems in which they operate. STUDY DESIGN AND SETTING: The findings from a rapid review of global insights on trial informativeness, a content analysis of internationally published clinical trial guidance documents, and qualitative interviews with trial stakeholders were compared. Actions and processes to improve trial informativeness that were verbatim or conceptually similar were extracted and organized under a shared framework. Supporting descriptors were compared and synthesized to capture core learnings that consistently appeared across all evidence sources. RESULTS: Comparison of the three research strands identified a set of 12 good practice actions spanning trial design, conduct, and knowledge mobilization. These actions reflect consistent priorities identified across evidence, guidance, and stakeholder perspectives. Their implementation involves multiple actors across the lifecycle of a trial. All good practice actions identified could apply to funders and/or sponsors, and trial investigators. Other stakeholders include regulatory authorities, patient or community representatives, ethics bodies, policymakers, and so on. CONCLUSION: The good practice actions identified to strengthen research systems that contribute to informative trials warrant standalone consideration within a wider mapping exercise, as they address broad drivers of trial quality and support improvements both within and beyond individual studies. Future work should focus on applying, evaluating, and refining these actions to ensure they remain relevant across diverse trial settings and contexts.
引用
- Prowse SR, Brazzelli M, Bain J, et al. Trial informativeness across research practices: initial findings from a mapping exercise. J Clin Epidemiol. 2026. PMID: 41999958. doi:10.1016/j.jclinepi.2026.112274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。